Milestone Scientific Inc. (MLSS) Stock Price & Analysis
Milestone Scientific Inc. (MLSS) fell 2.94% to USD 0.39 as of July 25, 2026 at 05:56 UTC, according to Nexqual real-time market data.
MLSS last closed at USD 0.4; the session ranged USD 0.39–0.43 on volume of 103,440 shares. Market capitalization is $34.51M, with a 52-week range of USD 0.22–0.68 (ASE). Source: Nexqual, July 25, 2026 at 05:56 UTC.
Key Statistics (as of July 25, 2026 at 05:56 UTC)
| Price | USD 0.39 |
|---|---|
| Change | ▼ 2.94% (down) |
| Previous Close | USD 0.4 |
| Open | USD 0.42 |
| Day Range | USD 0.39 – 0.43 |
| 52-Week Range | USD 0.22 – 0.68 |
| Volume | 103,440 shares |
| Market Cap | $34.51M |
| Exchange | ASE |
Technical Analysis (MLSS)
Nexqual's technical model rates MLSS "STRONG BUY" based on 5 bullish and 0 bearish signals across 125 daily candles, as of July 25, 2026 at 05:56 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 48.03 (neutral) |
| vs SMA50 | Above (USD 0.37) |
| MACD | 0.02 (positive) |
Analyst Ratings (MLSS)
Wall Street analysts rate MLSS "None" based on 2 analysts, with a mean price target of USD 1 (range USD 1–1), per Nexqual as of July 25, 2026 at 05:56 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 2 |
| Mean Target | USD 1 |
| High Target | USD 1 |
| Low Target | USD 1 |
| Buy / Hold / Sell | 2 / 0 / 0 |
Earnings (MLSS)
| Next Earnings Date | 2026-08-13 |
|---|---|
| EPS Estimate | USD -0.01 |
| Revenue Estimate | $2.70M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.01 vs est -0.02 ▲ beat |
| 2025-12-31 | USD -0.01 vs est -0.02 ▲ beat |
| 2025-09-30 | USD -0.01 vs est -0.01 ▲ beat |
| 2025-06-30 | USD -0.02 vs est -0.01 ▼ miss |
Source: Nexqual, July 25, 2026 at 05:56 UTC.
Financials & Fundamentals (MLSS)
| Total Revenue | $8.90M |
|---|---|
| Revenue Growth (YoY) | -3.20% |
| Gross Margin | +71.03% |
| Operating Margin | -38.30% |
| Profit Margin | -51.30% |
| ROE | -135.38% |
| Debt / Equity | 43.12 |
| Current Ratio | 1.51 |
| Total Cash | $1.19M |
| Total Debt | $985,348 |
| Free Cash Flow | $369,812 |
Source: Nexqual, July 25, 2026 at 05:56 UTC.
Financial Health Score (MLSS)
Nexqual rates Milestone Scientific Inc.'s overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 05:56 UTC.
| Growth | Mixed — Revenue +4.0% YoY (annual), slow |
|---|---|
| Profitability | Weak — Not yet profitable — scaling phase |
| Balance Sheet | Solid — $1M cash, no debt |
| Cash Flow | Mixed — FCF $370K, slim 4.1% margin |
| Efficiency | Critical — ROE -135%, ROA -33.2% |
Ownership (MLSS)
| Insider Ownership | +16.06% |
|---|---|
| Institutional Ownership | +5.06% |
| Shares Outstanding | 88.45M |
| Float | 70.62M |
| Short % of Float | +0.37% |
Source: Nexqual, July 25, 2026 at 05:56 UTC.
Leadership (MLSS)
Milestone Scientific Inc. is led by Eric C. Hines (age 57), CEO, President & Director, per Nexqual as of July 25, 2026 at 05:56 UTC.
| CEO, President & Director | Eric C. Hines (age 57) |
|---|---|
| Executive Chairman | Benedetta I. Casamento (age 58) |
| Vice President of Finance | Keisha Harcum M.B.A., M.S. |
Major Backers & Investors (MLSS)
Notable institutional backers of Milestone Scientific Inc. include Fidelity, Citadel, LPL Financial LLC, according to Nexqual as of July 25, 2026 at 05:56 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Fidelity | 0.57% |
| Citadel | 0.19% |
| LPL Financial LLC | 0.14% |
| Mariner, LLC | 0.14% |
| World Investment Advisors | 0.12% |
| Carnegie Investment Counsel | 0.11% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 4.85% |
| Geode Capital | 0.7% |
| State Street | 0.16% |
| Northern Trust | 0.13% |
Source: Nexqual, July 25, 2026 at 05:56 UTC.
From Milestone Scientific Inc.'s Latest SEC 10-K Filing (filed 2026-03-31)
Key Strengths & Strategy (as disclosed to the SEC)
- Our proprietary DPS Dynamic Pressure Sensing Technology allows the CompuFlo Epidural System to provide objective visual and audible in-tissue pressure feedback that allows anesthesiologists to identify and confirm placement in the epidural space.   Our CompuFlo Epidural System provides an objective tool that we believe consistently and accurately identifies the epidural space by detecting the difference in pressure between the ligamentum flavum and the intradural tissue.
- Class I devices are those devices whose safety and effectiveness can reasonably be ensured through general controls, such as adequate labeling, pre-market notification, and adherence to the FDA's Quality System Regulation ("QSR"), also referred to as "Good Manufacturing Practices" ("GMP") regulations.
- The Company's products, including the Wand® STA System, dental handpieces used with the Wand® and Wand® STA Systems, which are classified as Class IIa medical devices and the CompuFlo® Epidural System, which is classified as a Class IIb medical device, are currently authorized for sale in the European Union under certificates issued pursuant to the former European Medical Devices Directive ("MDD").
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RVP | Retractable Technologies, Inc. | USD 0.68 | ▲ 0% |
| INFU | InfuSystems Holdings, Inc. | USD 9.12 | ▲ 2.47% |
| VNRX | VolitionRX Limited | USD 1 | ▼ 3.85% |
| PAVM | PAVmed Inc. | USD 4.74 | ▲ 0.42% |
| IMDX | Insight Molecular Diagnostics I | USD 4.74 | ▼ 5.01% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 05:56 UTC. This page is informational and not investment advice.